Over the years, the company has established a large number of the state-of-the-art technologies and platforms necessary for development and production of therapeutic monoclonal antibodies. These include preparation and screening of hybridomas, antibody engineering and humanization, cell line construction and screening, CHO cell based culture platforms for high-density antibody expression, fermentation and purification, advanced analytical technologies for antibody characterization, antibody drug formulation, and GMP production.